adocia_logo.jpg
Adocia Initiates BC LisPram Phase 1 Clinical Trial in Pump for People with Type 1 Diabetes
June 29, 2021 12:00 ET | Adocia
For the first time, a unique combination of two key hormones involved in glycemic control, a rapid acting insulin analog and an amylin analog, is tested in a single pumpBioChaperone® Lispro and...
adocia_logo.jpg
ADOCIA Announces M1Pram Clinical Data Presentation at the American Diabetes Association® 81ˢᵗ Scientific Sessions
June 15, 2021 01:30 ET | Adocia
LYON, France, June 15, 2021 (GLOBE NEWSWIRE) -- ADOCIA (Euronext Paris: FR0011184241 – ADOC), a clinical-stage biopharmaceutical company specializing in the development of innovative formulations of...
adocia_logo.jpg
Adocia Expands Clinical Development to Obesity with Patent Applications on Short-Acting Multihormonal Combinations Administered by Pumps
May 26, 2021 01:30 ET | Adocia
Three patent families have been filed to cover novel hormonal combinations: pramlintide-exenatide and glucagon-exenatide – both combinations demonstrated promising effects in obesity...